Epigenetic Treatment Options in Urothelial Carcinoma

Area of Science:

• Oncology
• Epigenetics
• Molecular Biology

Background:

• Epigenetic regulators, including DNA methyltransferases, demethylases, histone methyltransferases, demethylases, acetyl transferases, and histone deacetylases (HDACs), are frequently mutated, dysregulated, or imbalanced in urothelial carcinoma (UC) compared to other cancers.
• The frequent alterations in epigenetic regulators suggest they represent a potential therapeutic vulnerability in UC.
• Targeting epigenetic regulators in cancer therapy is complex due to their broad cellular functions and potential off-target effects of inhibitors.

Purpose of the Study:

• To present a standard, multidimensional approach for analyzing the cellular and molecular functions of individual HDAC enzymes in UC pathogenesis.
• To evaluate the suitability of HDAC enzymes as therapeutic targets in UC.
• To assess the antineoplastic efficacy of isoenzyme-specific HDAC inhibitors for UC treatment.

Main Methods:

• Detailed analysis of individual histone deacetylase (HDAC) enzyme functions.
• Evaluation of HDAC enzymes as potential targets for UC therapy.
• Preclinical assessment of isoenzyme-specific HDAC inhibitors' antineoplastic capacity.

Main Results:

• The study outlines a systematic approach to dissect the roles of specific HDACs in UC.
• This methodology allows for the targeted evaluation of HDAC inhibitors' effectiveness against UC.
• The presented approach serves as a prototype for preclinical evaluation of other epigenetic therapies.

Conclusions:

• Targeting epigenetic regulators, particularly HDACs, presents a significant therapeutic opportunity for urothelial carcinoma.
• A multidimensional evaluation strategy is crucial for understanding the impact of epigenetic alterations and for developing effective inhibitors.
• The proposed analytical framework can guide the preclinical development of novel epigenetic anticancer treatments.